Immunocytochemical Characterization of Alzheimer Disease Hallmarks in APP/PS1 Transgenic Mice Treated with a New Anti-Amyloid-β Vaccine

Figure 2

EB101 vaccine prevents development of AD hallmarks in the brains of PS1/APP transgenic mice. Comparative photomicrographs of hippocampal brain regions at the end of preventive treatment (phase I) showing the effects on the AD-like hallmark reduction through immunoreactivity against Aβ ((a)–(c)), NTFs ((d)–(f)), GFAP ((g)–(i)), CD45RA ((j)–(l)), and CD3 ((m)–(o)).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)

(n)

(o)